Leading Russian drugmakers and foreign companies operating in the local market have called on the Russian government to change the existing rules for public procurements of drugs in Russia and to optimize the existing state measures for the support of the domestic pharmaceutical companies, according to recent statements, made by representatives of producers, reports The Pharma Letter’s local correspondent.
According to Victor Dmitriev, head of the Association of Russian Pharmaceutical Manufacturers, last year, due to imperfection of the Russian legislation in the field of drug public procurements, at least 65,000 auctions across the country to buy drugs for state needs were cancelled.
According to producers, there is a need to design a separate regulation of public procurements of drugs in Russia, that will provide an opportunity for local hospitals to use a more flexible approach during the choice of their suppliers and to achieve bigger savings during procurements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze